Rosuvastatin: Role in Cardiovascular High-risk Patient
Fuente:
Redalyc
Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Universidad Nacional de Colombia
2013
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1876425538524938240 |
|---|---|
| author | John E. Feliciano-Alfonso |
| author_facet | John E. Feliciano-Alfonso |
| contents | Rosuvastatin: Role in Cardiovascular High-risk Patient John E. Feliciano-Alfonso Medicina dyslipidemias Hydroxymethylglutaryl cardiovascular diseases CoA Reductase Inhibitors CostEffectiveness Evaluation (MesH) Statins are the lipid-lowering drug family of ¿rst choice in situations of hypercholesterolemia or mixed dyslipidemia with predominant increase in cholesterol. The evidence shows conclusively that each one of the commercially available statins have proven bene¿ts on outcomes of cardiovascular morbidity and mortality. However, rosuvastatin has certain pharmacokinetic ef¿cacy and cost-effectiveness characteristics that make it an attractive molecule to be the statin of choice in patients at high cardiovascular risk. 2013 artículo científico 2357-3848 https://www.redalyc.org/articulo.oa?id=576363533007 en http://www.redalyc.org/revista.oa?id=5763 Revista de la Facultad de Medicina application/pdf Universidad Nacional de Colombia Revista de la Facultad de Medicina (Colombia) Num.1 Vol.61 |
| format | Artículo científico |
| id | redalyc_576363533007 |
| institution | Redalyc |
| language | en |
| publishDate | 2013 |
| publisher | Universidad Nacional de Colombia |
| spellingShingle | Rosuvastatin: Role in Cardiovascular High-risk Patient John E. Feliciano-Alfonso Medicina dyslipidemias Hydroxymethylglutaryl cardiovascular diseases CoA Reductase Inhibitors CostEffectiveness Evaluation (MesH) Rosuvastatin: Role in Cardiovascular High-risk Patient John E. Feliciano-Alfonso Medicina dyslipidemias Hydroxymethylglutaryl cardiovascular diseases CoA Reductase Inhibitors CostEffectiveness Evaluation (MesH) Statins are the lipid-lowering drug family of ¿rst choice in situations of hypercholesterolemia or mixed dyslipidemia with predominant increase in cholesterol. The evidence shows conclusively that each one of the commercially available statins have proven bene¿ts on outcomes of cardiovascular morbidity and mortality. However, rosuvastatin has certain pharmacokinetic ef¿cacy and cost-effectiveness characteristics that make it an attractive molecule to be the statin of choice in patients at high cardiovascular risk. 2013 artículo científico 2357-3848 https://www.redalyc.org/articulo.oa?id=576363533007 en http://www.redalyc.org/revista.oa?id=5763 Revista de la Facultad de Medicina application/pdf Universidad Nacional de Colombia Revista de la Facultad de Medicina (Colombia) Num.1 Vol.61 |
| title | Rosuvastatin: Role in Cardiovascular High-risk Patient |
| topic | Medicina dyslipidemias Hydroxymethylglutaryl cardiovascular diseases CoA Reductase Inhibitors CostEffectiveness Evaluation (MesH) |
| url | https://www.redalyc.org/articulo.oa?id=576363533007 |